You are here

Home » City of Hope National Medical Center

City of Hope National Medical Center

1500 E. Duarte Road
Duarte, CA 91010
United States

Activation of Anti-Leukemia Immunity by Targeting Protein Arginine Methyltransferase

Leukemia

Childhood acute myeloid leukemia (AML) patients harboring a genetic change called “MLL gene rearrangement (MLL-r)”, have a particularly poor outcome, with a five-year survival rate ~56%. Those patients, accounting for ~15% of all childhood AML patients, are associated with high risk of disease come-back. Currently, immunotherapies, which mobilize a patient’s own T cells to eliminate cancer cells, have proven effective against other pediatric leukemias, particularly acute lymphoblastic leukemia.

Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma

Neuroblastoma

Lay Summary: This project is focused on developing a safe and effective therapy for treating high-risk neuroblastoma (NB). NB is one of the most common childhood neoplasms and accounts for 15% of all pediatric cancer deaths. The single most important factor determining the treatment options and prognosis of NB patients is risk stratification. Survival is excellent in low- and intermediate-risk groups. Localized perinatal adrenal tumors often regress spontaneously.

Featured Hero

Chris Ramirez

Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
Read more »